Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379285511> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W4379285511 endingPage "1047" @default.
- W4379285511 startingPage "1047" @default.
- W4379285511 abstract "1047 Background: HER2 REAL (NCT04857619) is the first multi-country, retrospective study exploring the treatment practices and outcomes in patients (pts) with HER2+ locally advanced, unresectable (u)/metastatic (m) breast cancer (BC) from routine clinical care in the APAC and LATAM. Methods: Adult HER2+ u/mBC pts diagnosed since reimbursement or wider access of trastuzumab emtansine (T-DM1) or 01 Jan 2017, whichever was earlier with ≥12 months (mo) of follow-up data from index date (u/mBC diagnosis) and treated with ≥1-line of therapy (LOT) were enrolled per medical chart review from 6 countries. Here we present interim descriptive analyses (cut-off 30 June 2022) on demographics, clinical characteristics, and treatment patterns. Results: Of the 763 enrolled pts, 370 with median (range) age of 55 (20–81) yrs from Hong Kong, Korea, Singapore, and Taiwan were eligible for interim analyses; 368 (99.5%) were female with 210 (57.1%) postmenopausal. A total of 210 (57.1%) pts with reported data had a median time of 2 (0–18) yrs from initial BC diagnosis to u/mBC relapse. At index date, majority had ductal carcinoma (227/254 [89.4%]), visceral (255/355 [71.8%]), and non-visceral (258/355 [72.3%]) metastases; 80/355 (22.5%) had CNS metastases. Family history of BC was reported by 45/370 (12.2%) pts completing the questionnaire; 209/370 (56.5%) had hormone receptor-positive BC. Treatments reported in the first to fifth line were quite variable. HER2-directed therapy was received by 323/367 (88.0%) in LOT1 (mainly trastuzumab [TRA] and pertuzumab [PTZ]-based) and 298/343 (86.9%) in LOT2 (mainly T-DM1). Median duration of LOT1 and LOT2 were 7.8 (0–130) and 5.0 (0–100) mo, respectively, that decreased to 2.3 (0–30) mo in LOT5. The prime reason for treatment discontinuation was disease progression (LOT1: 294 [80.1%]; LOT2: 273 [79.6%]; LOT3: 187 [68.5%]). Serious adverse effects from treatments were rare (LOT1: 7 [1.9%]; LOT2: 10 [2.9%]; LOT3: 5 [1.8%]). Conclusions: The interim analyses show heterogeneous treatment patterns in real-world among pts with HER2+ u/mBC progressing on HER2-directed therapies possibly due to access disparity in these 4 Asian countries. Clinical trial information: NCT04857619 . [Table: see text]" @default.
- W4379285511 created "2023-06-05" @default.
- W4379285511 creator A5004864286 @default.
- W4379285511 creator A5032942551 @default.
- W4379285511 creator A5033700679 @default.
- W4379285511 creator A5059830079 @default.
- W4379285511 creator A5069050806 @default.
- W4379285511 creator A5078643365 @default.
- W4379285511 creator A5089248850 @default.
- W4379285511 date "2023-06-01" @default.
- W4379285511 modified "2023-09-27" @default.
- W4379285511 title "Real-world treatment patterns in patients with HER2+ unresectable or metastatic breast cancer: Interim results from HER2 REAL Asia cohort." @default.
- W4379285511 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.1047" @default.
- W4379285511 hasPublicationYear "2023" @default.
- W4379285511 type Work @default.
- W4379285511 citedByCount "0" @default.
- W4379285511 crossrefType "journal-article" @default.
- W4379285511 hasAuthorship W4379285511A5004864286 @default.
- W4379285511 hasAuthorship W4379285511A5032942551 @default.
- W4379285511 hasAuthorship W4379285511A5033700679 @default.
- W4379285511 hasAuthorship W4379285511A5059830079 @default.
- W4379285511 hasAuthorship W4379285511A5069050806 @default.
- W4379285511 hasAuthorship W4379285511A5078643365 @default.
- W4379285511 hasAuthorship W4379285511A5089248850 @default.
- W4379285511 hasConcept C121608353 @default.
- W4379285511 hasConcept C126322002 @default.
- W4379285511 hasConcept C143998085 @default.
- W4379285511 hasConcept C187212893 @default.
- W4379285511 hasConcept C195910791 @default.
- W4379285511 hasConcept C2775930923 @default.
- W4379285511 hasConcept C2779786085 @default.
- W4379285511 hasConcept C29456083 @default.
- W4379285511 hasConcept C530470458 @default.
- W4379285511 hasConcept C71924100 @default.
- W4379285511 hasConcept C72563966 @default.
- W4379285511 hasConceptScore W4379285511C121608353 @default.
- W4379285511 hasConceptScore W4379285511C126322002 @default.
- W4379285511 hasConceptScore W4379285511C143998085 @default.
- W4379285511 hasConceptScore W4379285511C187212893 @default.
- W4379285511 hasConceptScore W4379285511C195910791 @default.
- W4379285511 hasConceptScore W4379285511C2775930923 @default.
- W4379285511 hasConceptScore W4379285511C2779786085 @default.
- W4379285511 hasConceptScore W4379285511C29456083 @default.
- W4379285511 hasConceptScore W4379285511C530470458 @default.
- W4379285511 hasConceptScore W4379285511C71924100 @default.
- W4379285511 hasConceptScore W4379285511C72563966 @default.
- W4379285511 hasIssue "16_suppl" @default.
- W4379285511 hasLocation W43792855111 @default.
- W4379285511 hasOpenAccess W4379285511 @default.
- W4379285511 hasPrimaryLocation W43792855111 @default.
- W4379285511 hasRelatedWork W188069312 @default.
- W4379285511 hasRelatedWork W2001196910 @default.
- W4379285511 hasRelatedWork W2092771806 @default.
- W4379285511 hasRelatedWork W2130521606 @default.
- W4379285511 hasRelatedWork W2158916914 @default.
- W4379285511 hasRelatedWork W2401868633 @default.
- W4379285511 hasRelatedWork W2896532861 @default.
- W4379285511 hasRelatedWork W2931400096 @default.
- W4379285511 hasRelatedWork W2934076975 @default.
- W4379285511 hasRelatedWork W2342209702 @default.
- W4379285511 hasVolume "41" @default.
- W4379285511 isParatext "false" @default.
- W4379285511 isRetracted "false" @default.
- W4379285511 workType "article" @default.